

4 0 9 2 6 5 8 - 0 2 0 2

We claim:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of: (1) sequences recited in SEQ ID NOS: 1-6; (2) complements of the sequences recited in SEQ ID NOS: 1-6; (3) reverse complements of the sequences recited in SEQ ID NOS: 1-6; (4) reverse sequences of the sequences recited in SEQ ID NOS: 1-6; (5) sequences having at least a 99% probability of being the same as a sequence recited in (1) – (4) above as determined using computer algorithm BLASTN; (6) sequences having at least 75% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (7) sequences having at least 90% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (8) sequences having at least 95% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (9) nucleotide sequences that hybridize to a sequence recited in (1) – (4) above under stringent hybridization conditions; (10) nucleotide sequences that are 200-mers of a sequence recited in (1) – (4) above; (11) nucleotide sequences that are 100-mers of a sequence recited in (1) – (4) above; (12) nucleotide sequences that are 40-mers of a sequence recited in (1) – (4) above; (13) nucleotide sequences that are 20-mers of a sequence recited in (1) – (4) above; and (14) nucleotide sequences that are degeneratively equivalent to a sequence recited in (1) – (4) above.
2. An oligonucleotide comprising at least 10 contiguous residues complementary to 10 contiguous residues of a nucleotide sequence recited in claim 1.
3. A genetic construct comprising an isolated polynucleotide of claim 1.
4. A host cell transformed with a genetic construct of claim 3.
5. An isolated polypeptide encoded by a polynucleotide of claim 1.
6. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 7-14; (b) sequences

11000.1068

having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 7-14, as determined using the computer algorithm BLASTP; (c) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 7-14, as determined using the computer algorithm BLASTP; (d) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 7-14, as determined using the computer algorithm BLASTP; and (e) sequences having at least 95% identity to a sequence provided in SEQ ID NOS: 7-14, as determined using the computer algorithm BLASTP.

7. An isolated polynucleotide encoding a polypeptide of claim 6.

8. An isolated polypeptide comprising at least a functional portion of an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 7-12; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 7-12, as determined using the computer algorithm BLASTP; (c) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 7-12, as determined using the computer algorithm BLASTP; (d) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 7-12, as determined using the computer algorithm BLASTP; and (e) sequences having at least 95% identity to a sequence provided in SEQ ID NOS: 7-12, as determined using the computer algorithm BLASTP.

9. A composition comprising a polypeptide according to any one of claims 6 and 8, and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

10. A composition according to claim 9, wherein the composition is a cosmetic composition.

11. A composition comprising a polynucleotide according to claim 1 and at least one component selected from the group consisting of: pharmaceutically acceptable carriers and immunostimulants.

12. A method for treating a disorder in a mammal, comprising administering a composition according to claim 9.

13. The method of claim 12, wherein the disorder is selected from the group consisting of: microbial infections and fungal infections.

14. A method for treating a disorder in a mammal comprising administering a composition according to claim 11.

15. The method of claim 14, wherein the disorder is selected from the group consisting of: microbial infections and fungal infections.

16. A transgenic organism comprising a host cell according to claim 4.

2025 RELEASE UNDER E.O. 14176